PDS Biotechnology Corporation Appoints Spencer Brown as Senior Vice President, General Counsel

PDS Biotechnology Corporation announced that Spencer Brown has joined PDS Biotech as Senior Vice President, General Counsel. Mr. Brown has extensive legal and compliance experience with large biotechnology, healthcare and pharmaceutical companies. Prior to joining PDS Biotech, Mr. Brown served as Senior Vice President, Legal Affairs and Chief Compliance Officer at Aclaris Therapeutics Inc. Prior to Aclaris, Mr. Brown served as Senior Legal Counsel at GE Healthcare. Mr. Brown holds a Bachelor of Arts from Princeton University and a Juris Doctorate from Carey Law School at the University of Pennsylvania. In addition, PDS Biotech has granted Mr. Brown non-statutory stock options to purchase 150,000 shares of PDS common stock as a material inducement to his employment with PDS Biotech pursuant to the Nasdaq Listing Rule. 5635(c)(4) and PDS Biotechs 2019 Incentive Plan, as amended. The PDS Biotechs 2019 Incentive Plan, as amended, provides for the granting of equity awards to new PDS Biotech employees. The stock option grant has an exercise price of $4.22, the closing price of PDS Biotechs common stock on June 2, 2022. The option grant vests over a period four years, with a quarter of the shares vesting on the first anniversary of the grant date (June 2, 2023) then monthly over the following 36 months, subject to presence in the company until the applicable vesting dates.